What is NORTHWEST BIOTHRPUTCS INC's earnings per share (EPS)?

NORTHWEST BIOTHRPUTCS INC (NWBO) reported diluted earnings per share of -$0.04 for fiscal year 2025. This represents a 42.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NORTHWEST BIOTHRPUTCS INC (NWBO) Financials

NWBO

Trailing 12 months to June 30, 2026

Revenue $2.2M +98.6% YoY

Net Income -$37.7M +54.2% YoY

EPS (Diluted) -$0.03 +50.0% YoY

Free Cash Flow -$49.8M -10.2% YoY

Market Cap $276.3M as of Oct 12, 2026

Price / Sales 127x on $2.2M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NWBO SEC filings page.

NORTHWEST BIOTHRPUTCS INC (NWBO) reported $2.2M in revenue over the twelve months to Jun 30, 2026, up 98.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NWBO FY2025 2026-10-03

Northwest Biotherapeutics remains development-stage: research spending is many times revenue, while operations still require substantial outside financing.

The 2025 improvement in operating cash flow, from -$57.0M in FY2024 to -$44.8M, did not make the model self-funding: free cash flow remained -$46.3M and financing provided $49.3M. That combination indicates reduced cash use, but continued dependence on capital raised elsewhere.

Revenue of $1.4M was dwarfed by research and development spending of $28.8M in FY2025, so reported losses primarily reflect the cost of advancing a development program rather than the economics of a scaled commercial operation. The net loss was $60.2M, while the operating margin remained -43.5%.

The balance sheet remains structurally constrained: current assets covered only 0.1x current liabilities, and total liabilities of $128.9M exceeded total assets of $81.3M. Negative equity of -$60.3M, alongside a rise in shares outstanding from 1.4B to 1.6B, shows that financing activity has supported operations without restoring a positive capital base.

Financial Health Signals

Financial health score not available

NORTHWEST BIOTHRPUTCS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-28.30

NORTHWEST BIOTHRPUTCS INC scores -28.30, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($276.3M) relative to total liabilities ($128.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

NORTHWEST BIOTHRPUTCS INC passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

NORTHWEST BIOTHRPUTCS INC reported a net loss of $60.2M while operations used $44.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

NORTHWEST BIOTHRPUTCS INC reported an operating loss of $59.9M against $8.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$807K

YoY+516.0%

QoQ+63.4%

5Y CAGR+14.2%

NORTHWEST BIOTHRPUTCS INC generated $807K in revenue in Q2 2026. This represents an increase of 516.0% from the same quarter a year earlier. Against the prior quarter it is up 63.4%.

EBITDA

-$10.9M

YoY+23.6%

QoQ-7.7%

NORTHWEST BIOTHRPUTCS INC's EBITDA was -$10.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 23.6% from the same quarter a year earlier. Against the prior quarter it is down 7.7%.

Net Income

-$9.2M

YoY+40.0%

QoQ-200.5%

NORTHWEST BIOTHRPUTCS INC reported -$9.2M in net income in Q2 2026. This represents an increase of 40.0% from the same quarter a year earlier. Against the prior quarter it is down 200.5%.

EPS (Diluted)

-$0.01

NORTHWEST BIOTHRPUTCS INC earned -$0.01 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$7.4M

YoY-5.4%

QoQ+41.7%

NORTHWEST BIOTHRPUTCS INC recorded an outflow of $7.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 5.4% from the same quarter a year earlier. Against the prior quarter it is up 41.7%.

Cash & Debt

$595K

YoY-86.2%

QoQ-66.7%

5Y CAGR-30.8%

10Y CAGR-12.0%

NORTHWEST BIOTHRPUTCS INC held $595K in cash against $52.0M in long-term debt as of Q2 2026.

Shares Outstanding

1.71B

QoQ+6.1%

5Y CAGR+14.3%

10Y CAGR+31.1%

NORTHWEST BIOTHRPUTCS INC had 1.71B shares outstanding in Q2 2026. Against the prior quarter it is up 6.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$5.7M

YoY-23.2%

QoQ+17.4%

5Y CAGR+0.9%

NORTHWEST BIOTHRPUTCS INC invested $5.7M in research and development in Q2 2026. This represents a decrease of 23.2% from the same quarter a year earlier. Against the prior quarter it is up 17.4%.

Capital Expenditures

$198K

YoY-34.9%

QoQ+53.5%

NORTHWEST BIOTHRPUTCS INC invested $198K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 34.9% from the same quarter a year earlier. Against the prior quarter it is up 53.5%.

Share Buybacks

Not reported for Q2 2026.

NWBO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NWBO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$2.2M	$1.4M-0.3%	$1.4M-28.5%	$1.9M+14.8%	$1.7M+67.5%	$1.0M-22.2%	$1.3M-46.4%	$2.4M+485.0%	$412K+22.6%	$336K-46.1%	$623K-64.2%	$1.7M+19.6%	$1.5M+79.7%	$809K+4.8%	$772K+7620.0%	$10K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$809K+4.8%	$772K+7620.0%	$10K
R&D Expenses	$23.6M	$28.8M-17.5%	$34.9M+25.8%	$27.7M-21.9%	$35.5M+74.9%	$20.3M-39.6%	$33.6M+138.5%	$14.1M-22.3%	$18.2M-45.8%	$33.5M-44.2%	$60.1M-41.7%	$103.1M+20.4%	$85.6M+95.0%	$43.9M+51.9%	$28.9M	N/A
SG&A Expenses	$28.9M	$32.5M-1.5%	$33.0M+11.1%	$29.7M-10.9%	$33.4M-0.1%	$33.4M-38.4%	$54.3M+233.2%	$16.3M-27.7%	$22.5M+80.7%	$12.5M+14.6%	$10.9M-40.7%	$18.3M+8.1%	$17.0M+37.0%	$12.4M-21.0%	$15.7M	N/A
Operating Income	-$50.3M	-$59.9M+9.9%	-$66.5M-19.8%	-$55.5M+17.4%	-$67.2M-27.5%	-$52.7M+39.1%	-$86.6M-209.5%	-$28.0M+32.5%	-$41.5M+24.1%	-$54.7M+31.0%	-$79.3M+37.2%	-$126.3M-24.9%	-$101.1M-82.3%	-$55.5M	N/A	N/A
EBITDA	N/A	-$57.9M+10.7%	-$64.8M-20.0%	-$54.0M+18.1%	-$65.9M-25.9%	-$52.4M+39.5%	-$86.5M-209.5%	-$28.0M+30.4%	-$40.2M+25.9%	-$54.2M+31.4%	-$79.1M+37.4%	-$126.2M-24.8%	-$101.1M-82.3%	-$55.5M	N/A	N/A
Interest Expense	$9.4M	$8.7M+11.9%	$7.8M+48.2%	$5.2M-13.6%	$6.1M+21.1%	$5.0M-41.4%	$8.5M+187.2%	$3.0M-69.9%	$9.9M+78.0%	$5.5M+45.2%	$3.8M-8.1%	$4.2M+317.0%	$996K+18.3%	$842K-93.7%	$13.4M	N/A
Income Tax	N/A	-$537K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	-$37.7M	-$60.2M+28.2%	-$83.8M-33.8%	-$62.6M+40.4%	-$105.0M-158.6%	$179.1M	N/A	-$20.8M+41.9%	-$35.8M+51.1%	-$73.1M+8.8%	-$80.2M+30.1%	-$114.7M+15.4%	-$135.6M-106.2%	-$65.8M	N/A	N/A
EPS (Basic)	N/A	-$0.04+42.9%	-$0.07-16.7%	-$0.06+40.0%	-$0.10-147.6%	$0.21+128.8%	-$0.73-1725.0%	-$0.04	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.35
EPS (Diluted)	-$0.03	-$0.04+42.9%	-$0.07-16.7%	-$0.06+40.0%	-$0.10-66.7%	-$0.06+91.8%	-$0.73-1725.0%	-$0.04	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	1.46B+17.3%	1.24B+110894.2%	1M+10.2%	1M+0.8%	1M+39.0%	725,129+28.5%	564,188	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$807K+516.0%	$494K+31.7%	$672K+190.9%	$200K-44.0%	$131K-74.3%	$375K+32.0%	$231K-48.1%	$357K-12.1%
R&D Expenses	$5.7M-23.2%	$4.9M-41.8%	$5.6M-47.2%	$7.5M-8.4%	$7.4M-10.4%	$8.4M+5.1%	$10.5M+41.2%	$8.1M+12.9%
SG&A Expenses	$6.7M-10.3%	$6.5M-30.0%	$8.6M+5.1%	$7.1M+0.6%	$7.5M-22.7%	$9.3M+15.4%	$8.2M+0.9%	$7.0M0.0%
Operating Income	-$11.6M+21.5%	-$10.9M+37.0%	-$13.5M+27.0%	-$14.3M+3.2%	-$14.8M+15.4%	-$17.3M-10.0%	-$18.5M-22.2%	-$14.8M-7.1%
EBITDA	-$10.9M+23.6%	-$10.1M+40.1%	N/A	N/A	-$14.3M+15.8%	-$16.9M-10.2%	-$18.1M	-$14.4M
Interest Expense	$1.8M-0.9%	$2.3M+46.4%	$2.6M+6.4%	$2.6M+26.0%	$1.8M+8.6%	$1.6M+5.5%	$2.5M+100.3%	$2.1M+24.6%
Net Income	-$9.2M+40.0%	-$3.1M+84.1%	$1.4M+104.9%	-$26.8M-38.5%	-$15.4M+13.9%	-$19.3M-5.6%	-$28.2M-101.9%	-$19.4M+17.6%
EPS (Basic)	-$0.010.0%	$0.00+100.0%	$0.00+100.0%	-$0.020.0%	-$0.01+50.0%	-$0.01+50.0%	-$0.020.0%	-$0.020.0%
EPS (Diluted)	-$0.01	$0.00+100.0%	$0.00+100.0%	-$0.020.0%	-$0.01	-$0.01	-$0.02	-$0.020.0%
Diluted Shares (Avg)	1.64B	1.58B+16.6%	N/A	1M+18.6%	1.44B	1.36B	N/A	1M+10.9%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

NWBO Balance Sheet

NWBO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$81.3M+204.1%	$26.7M-4.1%	$27.9M-11.0%	$31.3M-22.0%	$40.2M+22.1%	$32.9M+209.1%	$10.6M-56.9%	$24.7M-49.6%	$48.9M-7.6%	$52.9M-25.3%	$70.8M+25.4%	$56.5M+200.6%	$18.8M+148.1%	$7.6M+3470.8%	$212K
Current Assets	$5.5M+35.8%	$4.1M-1.5%	$4.1M-56.2%	$9.4M-45.5%	$17.3M+11.5%	$15.5M+384.7%	$3.2M-86.6%	$23.8M+1597.4%	$1.4M-82.2%	$7.9M-67.3%	$24.1M+64.6%	$14.6M-21.5%	$18.6M+150.0%	$7.5M+6220.3%	$118K
Cash & Equivalents	$3.0M+39.8%	$2.2M+2.3%	$2.1M-69.5%	$7.0M-54.1%	$15.2M+51.9%	$10.0M+2583.6%	$372K-98.3%	$22.2M+18894.9%	$117K-98.3%	$6.9M-68.5%	$21.8M+62.9%	$13.4M-27.6%	$18.5M+151.8%	$7.3M+30508.3%	$24K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$128.9M+6.3%	$121.2M+29.5%	$93.6M-41.3%	$159.4M-2.9%	$164.2M-58.5%	$395.8M+610.7%	$55.7M-22.5%	$71.8M-38.2%	$116.2M+46.4%	$79.4M+5.2%	$75.5M-17.5%	$91.5M+219.8%	$28.6M+21.0%	$23.6M-54.9%	$52.4M
Current Liabilities	$91.7M+34.3%	$68.3M+51.0%	$45.2M-64.1%	$126.0M-5.8%	$133.8M-65.0%	$382.4M+765.3%	$44.2M-36.7%	$69.8M-20.3%	$87.7M+14.8%	$76.4M+17.7%	$64.9M-13.4%	$75.0M+281.0%	$19.7M+83.3%	$10.7M-78.8%	$50.8M
Non-Current Liabilities	$37.2M-0.7%	$37.4M+26.0%	$29.7M+186.8%	$10.4M-65.9%	$30.4M+126.3%	$13.4M+16.7%	$11.5M+479.2%	$2.0M-76.7%	$8.5M+183.9%	$3.0M-71.5%	$10.5M-36.0%	$16.5M	$0-100.0%	$1.9M+15.2%	$1.6M
Long-Term Debt	$60.0M-4.2%	$62.7M+53.6%	$40.8M+89.5%	$21.5M-33.5%	$32.4M+119.3%	$14.8M+16.1%	$12.7M-24.3%	$16.8M-46.6%	$31.4M-0.9%	$31.7M+39.0%	$22.8M	N/A	N/A	N/A	N/A
Total Equity	-$60.3M+36.2%	-$94.5M-43.7%	-$65.8M+48.7%	-$128.1M-3.3%	-$124.0M+65.8%	-$362.9M-705.6%	-$45.1M+6.4%	-$48.1M+28.5%	-$67.3M-154.1%	-$26.5M-466.7%	-$4.7M+86.7%	-$35.0M-256.8%	-$9.8M+38.9%	-$16.1M+69.2%	-$52.2M
Retained Earnings	-$1.5B-4.2%	-$1.4B-6.2%	-$1.4B-4.8%	-$1.3B-8.8%	-$1.2B+13.1%	-$1.4B-63.0%	-$841.4M-2.1%	-$824.4M-4.5%	-$788.6M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$75.9M+157.0%	$80.1M+191.0%	$81.3M+204.1%	$30.6M+4.4%	$29.5M+4.7%	$27.5M-3.7%	$26.7M-4.1%	$29.3M-6.9%
Current Assets	$2.6M-58.2%	$6.2M+32.4%	$5.5M+35.8%	$7.2M+38.6%	$6.2M+23.7%	$4.7M-5.3%	$4.1M-1.5%	$5.2M-38.6%
Cash & Equivalents	$595K-86.2%	$1.8M-35.7%	$3.0M+39.8%	$4.6M+55.2%	$4.3M+49.8%	$2.8M+12.1%	$2.2M+2.3%	$2.9M-51.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%
Total Liabilities	$110.7M-14.8%	$118.1M-7.0%	$128.9M+6.3%	$139.3M+27.2%	$129.9M+24.1%	$127.0M+24.7%	$121.2M+29.5%	$109.4M+7.8%
Current Liabilities	$73.4M-12.6%	$83.0M-0.1%	$91.7M+34.3%	$87.9M+47.6%	$83.9M+49.4%	$83.1M+33.0%	$68.3M+51.0%	$59.6M+21.0%
Non-Current Liabilities	$37.4M+15.8%	$35.1M+20.0%	$37.2M-0.7%	$38.0M+11.6%	$32.3M+8.3%	$29.3M+49.4%	$37.4M+26.0%	$34.0M+72.4%
Long-Term Debt	$52.0M-19.7%	$59.4M-7.4%	$60.0M-4.2%	$72.2M+35.6%	$64.7M+26.8%	$64.1M+44.3%	$62.7M+53.6%	$53.3M+61.7%
Total Equity	-$45.2M+55.0%	-$50.5M+49.2%	-$60.3M+36.2%	-$108.6M-35.6%	-$100.4M-31.2%	-$99.5M-35.7%	-$94.5M-43.7%	-$80.1M-14.4%
Retained Earnings	-$1.5B-2.6%	-$1.5B-3.0%	-$1.5B-4.2%	-$1.5B-6.3%	-$1.5B-5.9%	-$1.5B-6.2%	-$1.4B-6.2%	-$1.4B-5.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable.

NWBO Cash Flow Statement

NWBO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$48.3M	-$44.8M+21.5%	-$57.0M-6.3%	-$53.6M-1.6%	-$52.8M-37.8%	-$38.3M-19.3%	-$32.1M-0.7%	-$31.9M+7.9%	-$34.6M+5.2%	-$36.5M+34.4%	-$55.7M+29.2%	-$78.6M-44.0%	-$54.6M-44.4%	-$37.8M-66.1%	-$22.8M	N/A
Depreciation & Amortization	N/A	$2.1M+18.3%	$1.7M+14.4%	$1.5M+21.8%	$1.3M+286.4%	$324K+272.4%	$87K+314.3%	$21K-98.4%	$1.3M+194.1%	$439K+132.3%	$189K+237.5%	$56K+409.1%	$11K0.0%	$11K-21.4%	$14K+40.0%	$10K
Stock-Based Compensation	N/A	$1.2M-65.1%	$3.5M-4.0%	$3.6M+38.5%	$2.6M-83.3%	$15.6M-70.0%	$52.0M+2753.1%	$1.8M-87.3%	$14.3M+1596.7%	$842K+563.0%	$127K-96.3%	$3.4M	$0-100.0%	$1.4M-57.9%	$3.2M-62.1%	$8.4M
Capital Expenditures	$1.4M	$1.5M+48.3%	$1.0M	N/A	N/A	N/A	N/A	$171K	N/A	N/A	N/A	N/A	N/A	-$1K-96.8%	$31K-36.7%	$49K
Free Cash Flow	-$49.8M	-$46.3M+20.3%	-$58.0M	N/A	N/A	N/A	N/A	-$32.0M	N/A	N/A	N/A	N/A	N/A	-$37.8M-65.9%	-$22.8M	N/A
Investing Cash Flow	-$1.7M	-$1.8M-79.0%	-$1.0M+70.5%	-$3.4M-18.4%	-$2.9M+51.8%	-$6.0M+26.1%	-$8.1M-2161.7%	-$360K-100.8%	$45.4M+21316.0%	$212K+104.3%	-$4.9M+26.8%	-$6.8M+81.4%	-$36.4M-3635300.0%	$1K+103.2%	-$31K+36.7%	-$49K
Financing Cash Flow	$41.7M	$49.3M-13.1%	$56.8M+7.6%	$52.8M+25.7%	$42.0M-12.8%	$48.1M-8.7%	$52.7M+429.5%	$10.0M+26.4%	$7.9M-77.0%	$34.3M-10.5%	$38.3M-59.3%	$94.2M+9.8%	$85.8M+75.3%	$49.0M+62.4%	$30.1M	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$240K	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$7.2M-7.2%	-$12.5M-32.8%	-$14.8M+26.8%	-$13.9M-68.7%	-$6.7M+58.7%	-$9.4M+24.1%	-$20.2M-19.0%	-$8.2M+40.9%
Depreciation & Amortization	$700K+40.0%	$771K+92.8%	N/A	N/A	$500K0.0%	$400K0.0%	$444K	$400K
Stock-Based Compensation	$181K-50.3%	$288K-25.2%	N/A	$273K-60.4%	$364K-67.7%	$385K-66.9%	N/A	$689K-57.5%
Capital Expenditures	$198K-34.9%	$129K+38.7%	$905K+1060.3%	$202K+14.8%	$304K-41.7%	$93K-61.1%	$78K	$176K-59.7%
Free Cash Flow	-$7.4M-5.4%	-$12.6M-32.9%	-$15.7M+22.7%	-$14.1M-67.6%	-$7.0M+58.2%	-$9.5M+24.8%	-$20.3M	-$8.4M+41.4%
Investing Cash Flow	-$198K+34.9%	-$129K-38.7%	-$905K-1060.3%	-$513K-191.5%	-$304K+41.7%	-$93K+61.1%	-$78K+81.3%	-$176K+59.7%
Financing Cash Flow	$7.4M-40.8%	$9.2M-21.5%	$13.6M-14.8%	$11.6M-0.5%	$12.4M-27.4%	$11.7M-2.9%	$15.9M+10.6%	$11.6M-32.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NWBO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NWBO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%0.0pp	100.0%0.0pp	100.0%
Operating Margin	-4347.9%	-4812.4%	-2873.1%	-3991.7%	-5244.0%	-6708.4%	-1161.0%	-10068.2%	-16273.2%	-12723.3%	-7261.9%	-6956.2%	-6857.1%	N/A	N/A
Net Margin	-4365.9%	-6062.1%	-3240.1%	-6240.8%	17823.5%	N/A	-863.6%	-8687.9%	-21768.8%	-12875.4%	-6598.1%	-9328.3%	-8132.1%	N/A	N/A
Return on Assets	-74.0%+239.4pp	-313.4%-88.8pp	-224.7%+110.7pp	-335.3%-781.4pp	446.0%	N/A	-195.6%-50.4pp	-145.1%+4.4pp	-149.6%+2.1pp	-151.6%+10.5pp	-162.1%+78.2pp	-240.3%+110.0pp	-350.2%	N/A	N/A
Current Ratio	0.060.0x	0.060.0x	0.090.0x	0.07-0.1x	0.13+0.1x	0.040.0x	0.07-0.3x	0.34+0.3x	0.02-0.1x	0.10-0.3x	0.37+0.2x	0.20-0.8x	0.95+0.3x	0.69+0.7x	0.00
Asset Turnover	0.020.0x	0.050.0x	0.070.0x	0.050.0x	0.030.0x	0.04-0.2x	0.23+0.2x	0.020.0x	0.010.0x	0.010.0x	0.020.0x	0.030.0x	0.04-0.1x	0.10+0.1x	0.05
FCF Margin	-3357.5%	-4199.1%	N/A	N/A	N/A	N/A	-1329.0%	N/A	N/A	N/A	N/A	N/A	-4672.6%	-2951.4%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-1438.0%	-2206.5%	-2009.5%	-7160.0%	-11281.7%	-4616.3%	-8008.2%	-4145.9%
Net Margin	-1142.6%	-621.3%	206.6%	-13414.5%	-11738.9%	-5158.1%	-12217.8%	-5426.9%
Return on Assets	-12.1%+39.9pp	-3.8%+66.5pp	1.7%+107.3pp	-87.6%-21.6pp	-52.0%+11.3pp	-70.3%-6.2pp	-105.6%-55.4pp	-66.1%+8.6pp
Current Ratio	0.040.0x	0.070.0x	0.060.0x	0.080.0x	0.070.0x	0.060.0x	0.060.0x	0.09-0.1x
Asset Turnover	0.010.0x	0.010.0x	0.010.0x	0.010.0x	0.000.0x	0.010.0x	0.010.0x	0.010.0x
FCF Margin	-912.9%	-2558.3%	-2331.7%	-7047.5%	-5337.4%	-2536.3%	-8770.1%	-2355.5%

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$60.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
NORTHWEST BIOTHRPUTCS INC NWBO	FY2025	$1.4M	-$60.2M	N/A	$276.3M	—
CYTODYN INC CYDY	FY2026	N/A	-$42.7M	N/A	$293.9M	—

Where NORTHWEST BIOTHRPUTCS INC Ranks

Frequently Asked Questions

What is NORTHWEST BIOTHRPUTCS INC's annual revenue?

NORTHWEST BIOTHRPUTCS INC (NWBO) reported $1.4M in total revenue for fiscal year 2025. This represents a -0.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is NORTHWEST BIOTHRPUTCS INC's revenue growing?

NORTHWEST BIOTHRPUTCS INC (NWBO) revenue declined by 0.3% year-over-year, from $1.4M to $1.4M in fiscal year 2025.

Is NORTHWEST BIOTHRPUTCS INC profitable?

No, NORTHWEST BIOTHRPUTCS INC (NWBO) reported a net income of -$60.2M in fiscal year 2025.

What is NORTHWEST BIOTHRPUTCS INC's EBITDA?

NORTHWEST BIOTHRPUTCS INC (NWBO) had EBITDA of -$57.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does NORTHWEST BIOTHRPUTCS INC have?

As of fiscal year 2025, NORTHWEST BIOTHRPUTCS INC (NWBO) had $3.0M in cash and equivalents against $60.0M in long-term debt.

What is NORTHWEST BIOTHRPUTCS INC's free cash flow?

NORTHWEST BIOTHRPUTCS INC (NWBO) recorded an outflow of $46.3M in free cash flow during fiscal year 2025. This represents a 20.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NORTHWEST BIOTHRPUTCS INC's operating cash flow?

NORTHWEST BIOTHRPUTCS INC (NWBO) recorded an outflow of $44.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are NORTHWEST BIOTHRPUTCS INC's total assets?

NORTHWEST BIOTHRPUTCS INC (NWBO) had $81.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are NORTHWEST BIOTHRPUTCS INC's capital expenditures?

NORTHWEST BIOTHRPUTCS INC (NWBO) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does NORTHWEST BIOTHRPUTCS INC spend on research and development?

NORTHWEST BIOTHRPUTCS INC (NWBO) invested $28.8M in research and development during fiscal year 2025.

How many shares does NORTHWEST BIOTHRPUTCS INC have outstanding?

NORTHWEST BIOTHRPUTCS INC (NWBO) had 1.61B shares outstanding as of fiscal year 2025.

What is NORTHWEST BIOTHRPUTCS INC's current ratio?

NORTHWEST BIOTHRPUTCS INC (NWBO) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is NORTHWEST BIOTHRPUTCS INC's return on assets (ROA)?

NORTHWEST BIOTHRPUTCS INC (NWBO) had a return on assets of -74.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NORTHWEST BIOTHRPUTCS INC's P/E ratio?

NORTHWEST BIOTHRPUTCS INC (NWBO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $276.3M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is NORTHWEST BIOTHRPUTCS INC's price-to-sales ratio?

NORTHWEST BIOTHRPUTCS INC (NWBO) trades at 127x sales, its market capitalization divided by revenue of $2.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $276.3M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does NORTHWEST BIOTHRPUTCS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, NORTHWEST BIOTHRPUTCS INC (NWBO) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $44.8M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is NORTHWEST BIOTHRPUTCS INC's debt-to-equity ratio negative or not reported?

NORTHWEST BIOTHRPUTCS INC (NWBO) has negative shareholder equity of -$60.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is NORTHWEST BIOTHRPUTCS INC's Altman Z-Score?

NORTHWEST BIOTHRPUTCS INC (NWBO) has an Altman Z-Score of -28.30, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is NORTHWEST BIOTHRPUTCS INC's Piotroski F-Score?

NORTHWEST BIOTHRPUTCS INC (NWBO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NORTHWEST BIOTHRPUTCS INC's earnings high quality?

NORTHWEST BIOTHRPUTCS INC (NWBO) reported a net loss of $60.2M while operations used $44.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can NORTHWEST BIOTHRPUTCS INC cover its interest payments?

NORTHWEST BIOTHRPUTCS INC (NWBO) reported an operating loss of $59.9M against $8.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.